Abstract We report the controlled release of tetracycline (Tet) HCl from a three-layered electrospun matrix for the first time. Five formulations of electrospun poly-ε-caprolactone (PCL) and poly(ethylene-co-vinyl acetate) (PEVA) have been designed, prepared as micro/nanofibre layers, and assayed for the controlled release of the clinically useful antibiotic Tet HCl with potential applications in wound healing and especially in complicated skin and skin-structure infections. Tet HCl was also chosen as a model drug possessing a good ultraviolet (UV) chromophore and capable of fluorescence together with limited stability. Tet HCl was successfully incorporated (essentially quantitatively at 3 %, w/w) and provided controlled release from multilayered electrospun matrices. The Tet HCl release test was carried out by a total immersion method on 2×2 cm 2
Introduction
In recent years, micro/nanofibrous matrices have gained widespread attention for their diverse potential in many biomedical applications, e.g. wound dressing, tissue engineering, enzyme immobilisation, and drug (including gene) delivery [1] [2] [3] . Such matrices are polymeric, therefore potentially chemically diverse, potentially biodegradable, and we have selected to work with two biocompatible and Food and Drug Administration (FDA)-approved polymers, poly-ε-caprolactone (PCL), and poly(ethylene-co-vinyl acetate) (PEVA). The interesting and distinct pharmaceutical properties of these matrices follow from their being on the micro/ nanoscale so they mimic the extracellular matrix (ECM) and therefore they also have the potential of enhancing cell attachment as their high surface area-to-volume ratio can be subject to surface modification by the addition of amine or carboxylic acid functional groups. These nanofibres [4] also have tuneable porosity, malleability (to form fibres, threads, sheets, and tubes), and their more recent possible biomedical applications include use in the construction of effective drug delivery systems [3] . The topographical similarity of these micro/nanoscale electrospun matrices with the ECM [3] is particularly interesting and it bodes well for their potential use as medical implants and in tissue engineering applications [5] [6] [7] .
As potential local controlled drug delivery systems, such electrospun fibres demonstrate good mechanical properties compared with hydrogels. They can also be used as carriers for both hydrophobic and hydrophilic drugs [7] . Among the methods for preparing nanofibres, e.g. drawing, template synthesis, phase separation, and self-assembly, electrospinning has emerged as a technology which is adaptable, reproducible, might be scalable, and should allow for fine control of the fibre dimensions [8] . These properties render the combination of an electrospun nanofibrous matrix and therapeutic agents beneficial for local delivery along with wound healing, tissue regeneration, or other biomedical applications [9] [10] [11] .
Wound healing and ulcer treatments require antibiotic therapy, intensive medical care, frequent hospitalisation, and even surgery. In 2004, the direct cost of wound care in the USA exceeded $15 billion [12] . Wounds are either acute or chronic. Acute wounds happen because of burns, physical or chemical injuries, while chronic wounds, which tend to heal slowly, develop with nutritional deficiencies, diabetes, persistent infections, or some genetic disorders [13, 14] . Traditional wound therapy depends largely on the wounddressing materials and the application of aseptic reagents. However, there is an increasing demand for biomaterials that not only provide physical and structural support but also are bioactive for wound healing [15] . Micro/nanofibrous matrices appear to be promising for wound dressings. As thin films, they combine light weight with good mechanical properties and a large surface area that prevents the compression of the injured tissue. Practically, they can cover large areas like burns [15] . As they are structurally ECM like, they can promote adhesion, proliferation, and differentiation of cells at the wound site [16] . In addition, the incorporation of an antibacterial agent stops or prevents bacterial infection that significantly compromises the healing process. It can also overcome several problems associated with the systemic administration of antibacterial agents, e.g. liver and renal toxicity, drug-resistant bacteria, and low levels of the antibiotic in the granulating tissue [17] . The release of an antibiotic drug has been studied from nanofibrous matrices made from different polymers such as PEVA [18] , poly-L-lactic acid [18] and blends of these two polymers [18] , polyvinyl alcohol [19] , and polylactide-coglycolide [20] . The main challenge is that nanofibrous matrices possess a high-surface area-to-volume ratio which leads to a large initial burst-release of the drug. Several attempts have been made to reduce this initial burst and elicit more control over a subsequent sustained release using formulations such as emulsions [21] , core-shell systems [22] , and nanotubes [23] . However, these formulations render the nanofibre preparation more complicated and they require control over a wide set of parameters.
These current studies are designed to demonstrate the incorporation and controlled release of an antibiotic drug, tetracycline hydrochloride (Tet HCl), from multilayered electrospun fibrous matrices for wound dressings. We have varied the polymer, the number of layers, and the drug location, resulting in different release profiles that may find uses in a variety of applications. Tet HCl was chosen as a clinically relevant antibiotic and also as a model drug possessing a good ultraviolet (UV) chromophore and capable of fluorescence together with limited stability. One facet of a multilayered fibrous system is the combination of different polymers with different properties and different release profiles. This could pave the way to engineering complex tissues with different structures, e.g. for tissue engineering [24, 25] . The layered matrices were made from two polymers, PCL and PEVA [18] . The use of PCL nanofibrous scaffolds as a dermal substitute has been reported and showed enhancement of cell proliferation [26] [27] [28] . PEVA (40 wt.% vinyl acetate) is a rubbery, biocompatible, and substantially amorphous copolymer. At 40 wt.% vinyl acetate, the percentage polyethylene crystallinity is no more than about 5 % (see, http://www.vitaldose.com/blog/crystallinity). PEVA is commonly used for rate-controlling membranes in drug delivery devices [29] . Five formulations have been designed and prepared, two formulations of one-layered matrices, one formulation of a two-layered matrix, and two formulations of threelayered matrices. This is the first time Tet HCl, or indeed any small molecule drug, has been reported in controlled release studies from a three-layered electrospun matrix.
Materials and methods

Materials
PCL (Mn, 70,000-90,000), PEVA (40 wt.% vinyl acetate), Tet HCl, and other chemicals and solvents were purchased from Sigma Aldrich, UK. Staphylococcus aureus (ATCC 25923) and Antimicrobial Susceptibility Test Discs were from Oxoid, UK. Micro/nanofibre fabrication via electrospinning Each polymer solution was loaded into a syringe and electrospun at 16.5 kV and a flow rate of 1.5 mL/h, with a distance between the tip of the needle and the collector of 13 cm. The flow rate was controlled by a syringe infusion pump (Cole Parmer). The electrospun micro/nanofibrous matrices were collected on two parallel metal electrodes covered with aluminium foil. To fabricate layered mats, each polymer solution was electrospun for a fixed deposition time (40 min) in a layer-by-layer manner. After 20 min, the rectangular collector was rotated through 180°for a second collection of 20 min. Five formulations were designed: one-layered PCL matrix with 3 % Tet HCl, one-layered PEVA matrix with 3 % Tet HCl, two-layered PCL/PEVA matrix with 3 % Tet HCl in each layer, three-layered PCL/PEVA/PCL matrix with 3 % Tet HCl in each layer, and three-layered PCL/PEVA/PCL with 3 % Tet HCl only in the PEVA layer.
Morphology
The surface morphology and the cross-sections of the layered electrospun matrices were observed by scanning electron microscopy (SEM; JEOL JSM-6480LV). The matrices were cut into small centimetre-sized pieces, and cross-sections of the layers obtained were freeze fractured in liquid nitrogen. The samples were sputter coated with gold (Edwards Sputter Coater 5150B) and then analysed by SEM with an accelerating voltage from 15 kV. The average fibre diameter was determined in layered electrospun matrices containing Tet HCl (3 %) and in a PCL-layer electrospun without the antibiotic. Some fibre diameter measurements were also taken after drug release for comparison. The average fibre diameter was determined by randomly selecting 20 fibres and measuring their diameters using Image J software (NIH, Bethesda, MD; http://rsb.info.nih.gov/ij/). The average thickness of each layer was determined by measuring the thickness of the crosssections from seven different points of two SEM images using the same software. The homogeneity of the deposition of each layer on the collector was observed by adding a dye (Rhodamine B) to the PEVA solution (which will become the middle layer) and then electrospinning the layers. After spinning each layer, the collector was imaged with a digital camera. Autofluorescence of the electrospun PCL fibres (without Tet HCl) and fluorescence of Tet HCl (3 % in PCL) were determined on a Leica DMI4000B inverted fluorescence microscope.
Encapsulation efficiency
To determine the encapsulation efficiency of the nanofibres, the electrospun mats were cut into small pieces (∼1 cm 2 ), weighed and then dissolved in CHCl 3 /MeOH (9:1 (v/v), 10 mL). The UV absorbance was measured at λ0360 nm, and the amount of Tet HCl in the fibres was then calculated using a Tet HCl calibration curve and compared with the theoretical value (3 %; n08).
Chemical integrity of Tet HCl in the matrices and following release
The chemical integrity of Tet HCl in the PCL and PEVA electrospun nanofibres was investigated by 1 H NMR spectroscopy (Bruker Avance spectrometer operating at 500 MHz for 1 H, 5 mm probe). The matrices were prepared with 10 % Tet HCl rather than 3 %. The matrices were cut into small pieces (5 mg) and then dissolved in deuteriated chloroform CDCl 3 (n02). A similar PCL (one-layered matrix) was prepared and the Tet HCl was released over 48 h, shaking at 37°C and 200 rotations per minute (rpm) into D 2 O (1 mL).
In vitro drug release studies
The micro/nanofibrous matrices were cut into 4 cm 2 squares. Each sample was placed in Tris buffer (10 mL; pH07.4) [18] or in phosphate-buffered saline (PBS; 10 mL; pH07.4) [22] in a glass vial. The vials were immersed in a water bath in a thermostatic shaking incubator at 37°C and 200 rpm. At specific time intervals (typically 24 h), each matrix sample was introduced into a new glass vial with buffer (10 mL). The samples were assayed by UV spectroscopy at λ0360 nm and the amount of Tet HCl released at each specific time was then calculated using a Tet HCl calibration curve and subsequently compared with the theoretical value (3 %; n03). In initial studies, we established the consistency of results by cutting three similar-sized squares from within a single mat (n03).
Antibacterial efficacy of Tet HCl-loaded layered micro/nanofibrous matrices
Commercially available Tet HCl-sensitive bacteria, S. aureus (ATCC 25923), were used to investigate the efficacy of Tet HCl-loaded in the designed formulations. For this, a modified Kirby-Bauer test was used [30] . The S. aureus suspension was incubated for 16 h and diluted with sterile Mueller-Hinton broth to obtain an absorbance value between 0.1 and 0.2 at 625 nm (equivalent to 0.5 McFarland standard). Then, 200 μL of the diluted bacteria solution was streaked onto the surface of the Mueller-Hinton agar plate (prepared previously according to the manufacturer's instructions) followed by placing the micro/nanofibrous matrices on the agar plates. Five groups of samples were tested: PCL containing no Tet HCl, PCL containing 3 % Tet HCl, PCL/PEVA containing 3 % Tet HCl in each layer, PCL/ PEVA/PCL containing 3 % Tet HCl in each layer, and PCL/ PEVA/PCL containing 3 % Tet HCl in the PEVA layer only. The matrices were cut (punched) into circular discs containing 30 μg Tet HCl which is equivalent to the amount in each commercially available Antimicrobial Susceptibility Test Disc containing Tet HCl. Three replicates of one formulation and one commercial Tet HCl disc as a positive control were placed on each agar plate. After incubation at 37°C for 24 h, the inhibition zones were measured. The discs were then introduced to new Mueller-Hinton agar plates prestreaked with fresh bacteria and incubated for another 24 h and the new inhibition zones were measured. This test took place for five successive days. The inhibition zone sizes (n0 3) were averaged and expressed as the mean± standard deviation. Student's t-test (Microsoft Excel) was used to determine any statistically significant differences between the formulations and the commercially available discs. P<0.01 is considered to be significant.
Results and discussion
Morphology of electrospun micro/nanofibrous matrices
Optical images
The homogeneity of the deposition of the upper layer over the previous layer was investigated by adding Rhodamine B to the PEVA second layer and observing the coloured coverage. The optical images of the matrices (Fig. 1) clearly show the first PCL layer (Fig. 1a) is white, while the second PEVA layer (Fig. 1b) is pink due to Rhodamine B and it shows full coverage over the first PCL layer. Finally, the third PCL layer completely hides the pink layer (Fig. 1c ). Figure 2 shows the SEM morphologies of the electrospun triple-layered PCL/PEVA/PCL micro/nanofibre matrix. The total thickness of the matrix is 1,050±50 μm (Fig. 2a) , and the thickness of each layer differs from one to another. The first electrospun layer was PCL with a thickness of 767±17 μm (Fig. 2b) . This decreases sharply to 77±14 μm for the middle PEVA layer (Fig. 2c) and 121±18 μm for the PCL upper electrospun layer (Fig. 2d) . The diameter of the fibres also differs. The diameter of the PEVA fibres is 1,246±221 nm, and the fibres fuse together at several points (Fig. 2e) . This might be explained by the solvent not evaporating completely upon the stretching of the PEVA fibres during the electrospinning process as any residual solvent may allow the fibres to fuse together, although (by NMR spectroscopy) there is only a small amount of residual CHCl 3 solvent. Comparing PEVA layers, there was no apparent difference between the fibres and their morphology in the second layer (Fig. 2f) and in an electrospun single layer of PEVA (Fig. 2e) . The diameter of the PCL fibres in the first layer is 702±120 nm with a smooth shape (Fig. 2g) . The diameter of the PCL fibres in the third layer is 1,916±532 nm. Comparing the PCL layers, the thickness of the third layer is much less than the first PCL layer; however, the diameter of the fibres in the third layer is larger than the first PCL layer. The accumulated charges of the electrospun fibres interrupt the build-up of the later deposited fibres which renders them less stretched, thus of larger diameter and with reduced layer thickness [31, 32] . With regard to before and after Tet HCl release from a three-layered matrix, the diameter of the PCL fibres in the first layer was slightly reduced on average from 702±120 (Fig. 2g ) to 666±125 nm (Fig. 2h) . The electrospun PCL-layer containing no drug was of thicker (double) fibre diameter 1,578±257 nm (Fig. 2i) . Whilst a similar shape is maintained, the morphology of the fibres is changed due to the absence of the ionic (charged) Tet HCl species during the electrospinning which increases the conductivity and thus decreases the diameter. Fluorescence microscopy demonstrates the fluorescence of Tet HCl in PCL nanofibres (Fig. 2j) .
Microscopy
Drug loading determination
Tet HCl loading in PCL electrospun fibres and PEVA electrospun fibres was 3.1±0.1 % and 2.95±0.1 % respectively compared with 3 % (w/w) initial strength. Essentially quantitative drug encapsulation efficiencies were achieved, 104± 5 % and 98±5 %, respectively.
Chemical stability of Tet HCl
It is well known that light, temperature, moisture, and duration of storage influence the stability of Tet leading to a decrease in its antibacterial activity and an increase in its toxicity [33, 34] . Changes in shape or hydrolysis of the acid or alkali labile functional groups which decorate the periphery of the Tet molecule may result in changes in the 1 H NMR [35] and UV spectroscopic data. The chemical integrity of Tet HCl after being spun under high electrical potential (16.5 kV) was therefore analysed. Tet HCl-loaded (Figs. 3 and 4) , the chemical integrity of loaded Tet HCl was maintained after the electrospinning process as all the signals of Tet HCl and the polymers could be observed, comparable with the literature data [34] . Such a spectroscopic measure of chemical stability after electrospinning has been reported in the analysis of nanofibres containing the antibiotic cefoxitin sodium (Mefoxin) [36] , a range of NSAIDs [37] , and even the protein bovine serum albumin [38] .
In vitro drug release studies
Release profiles of one-layered matrices
The Tet HCl release test was carried out by a total immersion method, in Tris at 37°C and 200 rpm, on electrospun fibrous mats cut from 2×2 cm 2 of aluminium foil. PEVA monolayers were difficult to handle if not intractable. The absorbance of Tet HCl at λ0360 nm was monitored as a function of time. The 1 H NMR spectra of authentic Tet HCl and Tet HCl released from PCL into D 2 O are essentially equivalent (Fig. 5a) ; the detail in the stack of the aromatic regions (Fig. 5b) 7.54 (t, J08 Hz) ppm for H-9, H-7, and H-8, respectively, entirely consistent with both an authentic sample and the literature data [34] . Figure 6 shows the cumulative Tet HCl release profile from electrospun fibrous PCL compared with electrospun fibrous PEVA, both one-layered matrices. As shown in Fig. 6 , PCL released approximately 92 % of Tet HCl within the first 3 h, whereas, PEVA released only 19 % within the same time. Following a small burst release, PEVA sustained the release of the Tet HCl over 8 days compared with PCL where the drug was liberated completely in the first day. It is likely that the difference in the release profile is due to the difference in the chemical and physical properties of the two polymers.
PCL is a hydrophobic and semi-crystalline polymer [39] . During the electrospinning process, the solvent evaporates as the polymer travels from the needle tip to the collector. In the case of the PCL, it appears that Tet HCl, being hydrophilic in nature in comparison to PCL, exhibits a greater affinity for the solvent than for the polymer and migrates with the solvent to the surface of the polymer during the solvent evaporation process. This results in the drug being mainly distributed on the surface and, consequently, a burst release. This phenomenon has also been observed in Tet HCl release from nanofibres of poly(lactic acid), a polymer with similar properties to PCL [18] . Similar behaviours have been proposed in order to speculate upon drug release profiles from PCL microparticles prepared by the solvent evaporation method [40, 41] . PEVA is a rubbery polymer [42] with a polar group of vinyl acetate, conferring a greater degree of hydrophilicity in comparison to PCL. Indeed, the air-water contact angle of PEVA membranes has been reported to be 56.1° [43] in comparison to 81.2°reported for PCL [44] , indicating PEVA's more hydrophilic nature. When electrospinning 12 % PEVA from a 9:1 chloroform/methanol mixture, the solvents did not evaporate completely (or evaporated slowly) from the polymer, causing the deposited fibres to fuse (Fig. 2e, f) . However, based on the release profile and physicochemical properties, it appears that hydrophilic Tet HCl was distributed more evenly through the more hydrophilic PEVA rather than partitioning into the solvent. This drug distribution resulted in a more sustained release. To further understand how PEVA sustains drug release, Peppas and co-workers observed a substantial pore collapse and proposed that the main mechanism of release from PEVA matrix systems is solute dissolution and diffusion through the generated water-filled pore structure [45, 46] . Release profiles of layered matrices
In Fig. 7 , the electrospun mats peeled from the aluminium foil show that the three-layered matrix, PCL/PEVA/PCL, retains its shape better than the ruffled two-layered matrix with one face composed of PEVA. Figure 8 displays the release profiles of layered matrices using our total immersion method on 2×2 cm 2 electrospun fibrous mats in Tris buffer and heated to 37°C. A twolayered matrix released 85 % of its content within the first 3 h and the rest a sustained release over the next 5 days. Upon the introduction of the third layer, the burst release was reduced to ∼55 % within the first 3 h and the release of the remaining drug was sustained to reach ∼80 % at day 15. The three-layered matrix PCL/PEVA/PCL with Tet HCl in the PEVA layer only, however, produced no initial burst, resulting in prolonged release reaching 50 % at day 15. Taking into the account the single-layer PEVA matrix release profile, 20 % release of its Tet HCl contents in a burst, the two-layered matrix was expected initially to show a burst release of the loaded drug with ∼50 % from release of almost all the drug in the PCL layer and then the remaining drug coming from the PEVA layer. The differences between the release from a PEVA one-layered matrix (of an intractable rubbery polymer) and the case of a twolayered matrix are due to the sticky properties of the PEVA which caused the one-layer PEVA sample to roll-up on handling and stick to itself in an irregular manner, whereas the two-layered matrix, with the PEVA layer supported by the PCL layer, essentially maintained its shape when cut and then peeled from the aluminium foil (Fig. 7) , making the PEVA surface of the two layers more available to interact with the buffer.
From the three-layered matrix, PCL/PEVA/PCL with Tet HCl in each layer, the initial burst was close to our prediction (about 60 %, 30 % coming from each PCL layer). However, there was then a sustained release for more than 8 days to reach about 80 % of the total loading released by day 15. We conclude that the PCL layer plays the role of a physical barrier which delays the diffusion of the buffer into the PEVA layer. PCL is a hydrophobic polymer and PEVA is a known ratecontrolling drug-release polymer [39, 42] . The water molecules have to diffuse through the hydrophobic polymer to reach the PEVA, then to diffuse through the PEVA and dissolve the Tet HCl incorporated in the PEVA, and diffuse out again. To further investigate this concept, we studied the release from PCL/PEVA/PCL three-layered matrix where the Tet HCl is only in the PEVA layer. We found that sandwiching the PEVA between two layers of PCL clearly sustained the release from about 3 (where a one-layered matrix of PEVA continued releasing 50 %, green lower line in Fig. 6 ) to 15 days (where a three-layered matrix with Tet only in the PEVA layer also continued releasing 50 %, pink lower line in Fig. 8 ). For a successful antibacterial wound dressing, an initial burst release would help to eliminate any invading bacteria, whereas, a sustained release antibiotic will secure the prevention of any relapse [36] . Achieving a delivery system capable of a burst release followed by a sustained release can be usefully incorporated in orthopaedic-related devices, potentially enhancing the wound healing processes, and further other applications may be in organ transplantation, periodontal devices, intravascular devices and vascular grafts [46, 47] . Of our obtained release profiles, the formulation PCL/PEVA/PCL with Tet HCl in each layer is most promising. However, each of the release profiles might be useful for a specific application, for example, the three-layered matrix with Tet HCl in the PEVA layer only, gave a release profile that could be favourable where no burst release, but rather a slow sustained release is required. Moreover, the layered design of the electrospun fibrous matrices is a platform for engineering tissues with several layers, e.g. blood vessels and skin. Employing this design to control drug release will enable an easy combination between a layered engineered tissue and the controlled release of a bioactive which are necessary requirements in support of organ regeneration. PCL and PEVA are FDA approved biocompatible polymers. The layered matrices neither swell nor shrink on contact with and during immersion in heated Tris or PBS buffer; there was no obvious erosion. The mats are not visibly frayed after 15 days under such conditions, with daily manipulation and constant heating and shaking. Whereas many papers on electrospinning nanofibres from a blend of a polymer and a drug end with a UV or related spectrophotometric release assay, and our UV, fluorescence, and NMR data are all entirely consistent with unchanged Tet HCl being released, the acid test of Tet HCl surviving electrospinning and then being biologically available by exiting the matrix must be antibacterial efficacy.
Antibacterial efficacy of Tet HCl release from the fibrous-layered matrices
The biological activity of the released Tet HCl was investigated using S. aureus bacteria inhibition experiments. Formulations of PCL/PEVA with Tet HCl in both layers, PCL/PEVA/PCL with Tet HCl in all layers, PCL/PEVA/PCL with Tet HCl only in the PEVA layer, and one layer of PCL with Tet HCl, were chosen. However, one-layered PEVA with Tet HCl has poor mechanical properties, in that it is such a sticky material, so it was omitted from the antibacterial assay as it was not practical to punch the PEVA circular discs which often tore on handling; robustness was achieved with a two-layer formulation, i.e. adding a PCL layer. Two controls were used, commercially available Antimicrobial Susceptibility Test Tet HCl-loaded discs (positive control) and electrospun nanofibrous PCL without any antibiotic (negative control). The samples were punched into circles containing ∼30 μg Tet HCl, chosen as this is the dose in the positive control discs. The test was conducted for 5 days to show any sustained release of the drug and its antibacterial activity. The results of the microorganism susceptibility tests are shown in Fig. 9 . On day 1, all the samples exhibited inhibition zones comparable to the positive control apart from the negative control, which unsurprisingly showed no inhibition zone and the formulation PCL/PEVA/PCL with Tet HCl in the PEVA only, which indicated a smaller inhibition zone demonstrating that no burst release was taking place. On day 2, the size of the inhibition zones decreased, however all our samples were comparable to the positive control. On day 3, the inhibition zones of the positive control and of the one-layer electrospun PCL containing Tet HCl decreased sharply, whereas the multilayered formulations were still showing significantly higher antibacterial effects (P<0.01). This shows that the inhibition zones were due to the sustained release of Tet HCl. On days 4 and 5, the multilayered formulations were still showing significantly higher antibacterial effects than the commercially available discs (P<0.01) (Fig. 9) . In addition to the above UV and NMR data, these biological activity results confirm that Tet HCl loaded into the micro/nanofibrous matrices maintains its biological function, unaffected by the 16.5 kV electrospinning process showing antimicrobial activity sustained over 5 days.
Earlier this year, the potential for electrospun matrices in localised drug delivery and related biomedical applications was highlighted [3] . We are only aware of one other research group that has published on a triple-layered mat. Yoon, Kim, and coworkers have reported the release of Rhodamine B as a model drug from various thicknesses of layered mats consisting of electrospun PCL and polyethylene oxide (PEO) micro/nanofibres [48] . They reported the release of a cationic peptide, a synthetic 15-mer (FKRLKKLFKKIWNWK, ∼2.06 kDa) called HPA3NT3 which carries seven positive charges at physiological pH and is a pore-forming and membrane disrupting antibiotic, acting in a similar manner to melittin [49] . The 15-mer peptide was encapsulated in the PEO layer with variation in the thickness of the PCL layers [48] . They continue their work on PCL and PEO monitoring the release of Rhodamine B [50] , earlier this year reporting ways to overcome edge-effects in layer-by-layer electrospun micro/nanofibrous mats of PCL and PEO with the ultimate goals of soft and hard tissue regeneration [51] .
In our studies, the first small molecule drug, Tet HCl has been successfully incorporated in and its release controlled from multilayered electrospun matrices without any loss in its chemical stability or bioactivity. Electrospinning provides good encapsulation efficiency of Tet HCl within the polymers. The introduction of the third layer to the twolayered formulation led to an increase in sustained release from 6 days to more than 15 days. The formulation PCL/ PEVA/PCL with Tet HCl in each layer could potentially be a successful wound dressing system as it gives a large initial (burst) release which is important to deal with the immediately invading bacteria, followed by a sustained release which will help to prevent any relapse. These biocompatible triple-layered electrospun matrices are also of interest as they can be further developed and studied for multilayered bioartificial replacement tissues, e.g. blood vessels and skin, where bioactive molecules can be incorporated and their release controlled.
